启愈生物技术(上海)有限公司
Location: China
Mentions in press and media 7
| Date | Title | Description |
| 29.01.2026 | QureBio Ltd. to Present at ASCO 2026 its Q-1802 Phase II Clinical Results | SHANGHAI, Jan. 29, 2026 /PRNewswire/ -- QureBio Ltd., a clinical-stage biotech company focusing on development of bispecific antibodies and other engineered Biopharmaceuticals for the treatment of cancer, inflammation, and other serious dis... |
| 05.06.2025 | QureBio Ltd. Completes Nearly CNY 100 Million Series C1 Financing Led by Efung Capital, accelerating clinical progress in global competition for core pipelines | SHANGHAI, June 5, 2025 /PRNewswire/ -- Qure Biotechnology (Shanghai) Co., Ltd. (QureBio) announced that it has completed a Series C1 financing round. The financing raised nearly CNY 100 million (approximately USD 14 million) and was led exc... |
| 05.06.2025 | Top 10 Startup and Tech Funding News – June 5, 2025 | It’s Thursday, June 5, 2025, and we’re back with your daily tech funding roundup, tracking where capital is flowing and which startups are laying the groundwork for what comes next. Today’s lineup spans defense tech, brain-computer interfac... |
| 05.06.2025 | QureBio Closes Nearly CNY 100M Series C1 Financing | QureBio, a Shanghai, China-based company developing bispecific and multispecific antibody and protein therapeutics, raised nearly CNY 100M (approx. $14M) in Series C1 funding. The round was led by Efung Capital. The company intends to use t... |
| 06.11.2024 | QureBio Ltd. to Present its Q-1802 Clinical PhaseⅡ Data at 2024 SITC 39th Annual Meeting | SHANGHAI, Nov. 6, 2024 /PRNewswire/ -- QureBio Ltd., a clinical-stage biopharmaceutical company focusing on development of bispecific antibodies and other engineered Biopharmaceuticals for the treatment of cancer, inflammation, and other se... |
| 21.12.2022 | QureBio Ltd. to Present its Q-1802 Clinical Phase Ⅰ Data at 2023 ASCO-GI Meetings | SHANGHAI, Dec. 21, 2022 /PRNewswire/ -- QureBio Ltd., a clinical-stage biopharmaceutical company focusing on development of bispecific antibodies and other engineered Biopharmaceuticals for the treatment of cancer, inflammation, and other s... |
| - | QureBio | “Qiyu Biological Technology (Shanghai) Co., Ltd.” |